Merck KGaA R&D Head: Biomarker Approach 'Further Validated' At ASCO

 
• By Sten Stovall
  
Tumor marker
Merck KGaA is using biomarkers to select patients for testing Tepotinib and M7824. • Source: Shutterstock

More from Anticancer

More from Therapy Areas